P620 Golimumab in ulcerative colitis: A multi-centre real-world experience

Kumar, Aditi; Slater, J; Jones, Judith; Troth, T; Baker, Graham; Love, Melanie; Nahal, J; Rattehalli, Deepa

doi:10.1093/ecco-jcc/jjx180.747

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Application of the exclusion criteria yielded fteen studies (9 manuscripts, 6 conference abstracts), encompassing a total of 1,212 patients (Table 1). [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] A diagnosis of CD was captured for 769 patients, and a diagnosis of UC was provided for 443 patients. 18,20,21 Nine studies were prospective in design, 16,18,19,21,23,24,[27][28][29] and seven were carried out at multiple institutions.…”

Section: Search Resultsmentioning

confidence: 99%

“…18,20,21 Nine studies were prospective in design, 16,18,19,21,23,24,[27][28][29] and seven were carried out at multiple institutions. 16,17,19,20,23,24,30 No phase IV trials were identi ed for inclusion. Two studies de ned deep remission (DR) beyond the minimum criteria of clinical remission and endoscopic remission -Magro 2016 included histologic remission de ned as a Geboe's score < 4, and Kaymak 2018 supplemented both histologic remission and two years of biochemical remission (fecal calprotectin < 150).…”

Section: Search Resultsmentioning

confidence: 99%

“…22,24 Two conference abstracts used the same cohort and reported rates of DR at different time points, therefore this cohort was only counted one time. 27,28 Ten studies featured only in iximab (IFX), 16, 18, 20-22, 24, 26-29 two used only adalimumab (ADA), 19,23 one study assessed golimumab, 30 and two studies incorporated both IFX and ADA. 17,25 Pineton de Chambrun 2016 reported that 65% of DR patients received concomitant therapy with AZA, whereas only 28% of their non-DR group was receiving concomitant AZA.…”

Section: Search Resultsmentioning

confidence: 99%

“…3) and found to be 43.6% (95% CI: 32.8-55.1%) in 146/323 patients. 16,18,23,24,30 Sensitivity analysis with De Vos 2013 removed resulted in a 46.6% deep remission rate at one year ( Supplementary Fig. 1).…”

Section: Achieving Deep Remission In Crohn's Disease and Ulcerative Cmentioning

confidence: 99%

See 3 more Smart Citations

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Alipour

Gulati

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background & Aims Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, RCTs may not be generalizable to clinical practice. In this systematic review with meta-analysis, we use real-world data (RWD) to determine rates of DR in IBD treated with anti-TNFα. Methods We completed a systematic search of MEDLINE and EMBASE on July 8, 2019 with review of major gastrointestinal conference abstracts from 2012-2019. Studies utilizing RWD (data not from phase I-III RCTs) of adult IBD patients treated with anti-TNFα agents were included. DR was defined by clinical and endoscopic remission at minimum. DR was assessed at 8 weeks, 6 months, 1 year, and 2 years.Results 29,033 publications were found on initial search. Fifteen publications, nine manuscripts and six conference abstracts, were included encompassing 1,212 patients (769 Crohn’s disease-CD, 443 ulcerative colitis-UC). Rate of DR was 36.4% (95%-CI: 12.6-69.4%) at eight weeks, 39.1% (95%-CI: 10.4-78%) at six months, 44.4% (95%-CI: 34.6-54.6%) at one year, and 36% (95%-CI: 18.7-58%) at two years. DR in CD at one year was 48.6% (95%-CI: 32.8-64.7%) and in UC was 43.6% (95%-CI: 32.8-55.1%).Conclusions The rate of DR was highest after one year of therapy, in nearly 45% of IBD patients treated with anti-TNFα. Similar rates were achieved between patients with UC and CD. The findings highlight the efficacy of anti-TNFα in real-world setting. Future studies using RWD can determine efficacy of newer IBD therapeutics in routine clinical practice.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Achieving Deep Remission In Crohn's Disease and Ulcerative Cmentioning

confidence: 99%

See 2 more Smart Citations

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Alipour

Gulati

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Background Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, real-world data (RWD) can provide information complementary to RCTs, specifically regarding treatment duration. In this systematic review with meta-analysis, we use real-world data (RWD) to determine rates of DR in IBD treated with anti-TNFα. Methods We completed a systematic search of MEDLINE and EMBASE on July 8, 2019 with review of major gastrointestinal conference abstracts from 2012 to 2019. Studies utilizing RWD (data not from phase I-III RCTs) of adult IBD patients treated with anti-TNFα agents were included. DR was defined by clinical and endoscopic remission at minimum. DR was assessed at 8 weeks, 6 months, 1 year, and 2 years. Risk of bias was assessed with the Newcastle Ottawa Scale. Results 29,033 publications were identified. Fifteen publications, nine manuscripts and six conference abstracts, were included encompassing 1212 patients (769 Crohn’s disease-CD, 443 ulcerative colitis-UC), and analyzed using Comprehensive Meta-Analysis. Rate of DR was 36.4% (95% CI 12.6–69.4%) at 8 weeks, 39.1% (95% CI 10.4–78%) at 6 months, 44.4% (95% CI 34.6–54.6%) at 1 year, and 36% (95% CI 18.7–58%) at 2 years. DR in CD at 1 year was 48.6% (95% CI 32.8–64.7%) and in UC was 43.6% (95% CI 32.8–55.1%). Conclusions The rate of DR was highest after 1 year of therapy, in nearly 45% of IBD patients treated with anti-TNFα. Similar rates were achieved between patients with UC and CD. The findings highlight the efficacy of anti-TNFα in real-world setting. Future studies using RWD can determine efficacy of newer IBD therapeutics in routine clinical practice.

show abstract

P620 Golimumab in ulcerative colitis: A multi-centre real-world experience

Cited by 2 publications

References 0 publications

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

Contact Info

Product

Resources

About